Summary of subgroup analysis by active treatment, timing of CD20 antibody therapy, HCT, receipt of targeted therapies, and type of COVID-19 vaccine
| . | Intervention arm . | Control arm . | Intervention vs control cohort . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pooled response rate (95% CI) . | I2(%) . | P . | Pooled response rate (95% CI) . | I2(%) . | P . | OR (95% CI) Heterogeneity . | P . | I2(%) . | P . | |
| Active therapy vs no active therapy | ||||||||||
| After second dose | 0.28 (0.08-0.48) | 83 | <.01 | 0.62 (0.39-0.86) | 94 | <.01 | 0.21 (0.06-0.67) | .02 | 75 | <.01 |
| After first dose | 0.42 (0.09-0.75) | 49 | .08 | 0.81 (0.66-0.95) | 0 | .62 | 0.19 (0.03-1.19) | .06 | 24 | .27 |
| CD-20 antibody therapy within 12 months vs CD-20 therapy 12 or more months | ||||||||||
| After second dose | 0.19 (0.00-0.50) | 88 | <.01 | 0.61 (0.41-0.82) | 88 | <.01 | 0.08 (0.01-0.59) | .02 | 57 | .04 |
| After first dose | Single study | Single study | Single study | |||||||
| Targeted therapy | ||||||||||
| After second dose | 0.35 (0.19-0.52) | 94 | <.01 | No controls | No analysis | |||||
| After first dose | Single study | No controls | No analysis | |||||||
| HSCT or cellular therapy within 12 months vs after 12 or more months | ||||||||||
| After second dose | 0.66 (0.43-0.88) | 0 | .63 | 0.68 (0.40-0.95) | 45 | .16 | 0.96 (0.11-8.74) | .94 | 36 | .21 |
| After first dose | Single study | Single study | Single study | |||||||
| BNT162b2 vs non-BNT162b2 vaccine type* | ||||||||||
| After second dose | 0.77 (0.40-1.00) | 98 | <.01 | 0.81 (0.56-1.00) | 87 | <.01 | 1.08 (0.20-5.92) | .90 | 64 | .04 |
| After first dose | 0.51 (0.13-0.90) | 86 | <.01 | 0.64 (0.36-0.91) | 73 | .01 | 0.59 (0.22-1.60) | .19 | 7 | .36 |
| . | Intervention arm . | Control arm . | Intervention vs control cohort . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pooled response rate (95% CI) . | I2(%) . | P . | Pooled response rate (95% CI) . | I2(%) . | P . | OR (95% CI) Heterogeneity . | P . | I2(%) . | P . | |
| Active therapy vs no active therapy | ||||||||||
| After second dose | 0.28 (0.08-0.48) | 83 | <.01 | 0.62 (0.39-0.86) | 94 | <.01 | 0.21 (0.06-0.67) | .02 | 75 | <.01 |
| After first dose | 0.42 (0.09-0.75) | 49 | .08 | 0.81 (0.66-0.95) | 0 | .62 | 0.19 (0.03-1.19) | .06 | 24 | .27 |
| CD-20 antibody therapy within 12 months vs CD-20 therapy 12 or more months | ||||||||||
| After second dose | 0.19 (0.00-0.50) | 88 | <.01 | 0.61 (0.41-0.82) | 88 | <.01 | 0.08 (0.01-0.59) | .02 | 57 | .04 |
| After first dose | Single study | Single study | Single study | |||||||
| Targeted therapy | ||||||||||
| After second dose | 0.35 (0.19-0.52) | 94 | <.01 | No controls | No analysis | |||||
| After first dose | Single study | No controls | No analysis | |||||||
| HSCT or cellular therapy within 12 months vs after 12 or more months | ||||||||||
| After second dose | 0.66 (0.43-0.88) | 0 | .63 | 0.68 (0.40-0.95) | 45 | .16 | 0.96 (0.11-8.74) | .94 | 36 | .21 |
| After first dose | Single study | Single study | Single study | |||||||
| BNT162b2 vs non-BNT162b2 vaccine type* | ||||||||||
| After second dose | 0.77 (0.40-1.00) | 98 | <.01 | 0.81 (0.56-1.00) | 87 | <.01 | 1.08 (0.20-5.92) | .90 | 64 | .04 |
| After first dose | 0.51 (0.13-0.90) | 86 | <.01 | 0.64 (0.36-0.91) | 73 | .01 | 0.59 (0.22-1.60) | .19 | 7 | .36 |
Non-BNT162b2 includes mRNA-1273, ChAdOx1, and Ad26 vaccines.